MedTrace Logo

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT04318080 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-09-24

Study results available
· View outcomes & findings →

Summary

This was a Phase 2 trial evaluating the effectiveness and safety of tislelizumab in participants with relapsed or hard-to-treat classical Hodgkin lymphoma (cHL). Participants were grouped by prior treatments. The main outcome was to assess overall response rate (ORR) across both cohorts. Participants continued receiving the study treatment until their disease got worse, side effects became too severe, or they chose to stop for other reasons.

Conditions

  • Classical Hodgkin Lymphoma

Interventions

DRUG

Tislelizumab

200 milligrams (mg) intravenously every 3 weeks (Q3W)

Sponsors & Collaborators

  • Lymphoma Study Association

    collaborator OTHER

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Herve Ghesguieres · Lymphoma Study Association

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-20
Primary Completion
2022-12-12
Completion
2024-08-29
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04318080 on ClinicalTrials.gov